Codiak aims to create a pipeline of drugs across a broad range of diseases, including those associated with currently “undruggable” targets. Leveraging exosomes’ tunable distribution profiles and natural delivery mechanism, we are developing a versatile drug design platform based on potent specific payloads and pharmacologically active surface engineering.

Codiak will define and engineer exosomes with single or multiple payloads directed against specific intracellular targets.

Codiak also has rights to a novel investigational drug candidate for pancreatic cancer, from The University of Texas, MD Anderson Cancer Center.